SLC5A2 and atherosclerosis: ,3,4 Based on the robust trial evidence, the American Diabetes Association and European Association for the Study of Diabetes guidelines have, since 2020, recommended SGLT2 inhibitors as first-line therapy for patients with or at high risk for ASCVD, heart failure, or chronic kidney disease.5